<DOC>
	<DOCNO>NCT02397954</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability Zimura® intravitreous injection combination anti-VEGF therapy subject Idiopathic Polypoidal Choroidal Vasculopathy ( IPCV ) .</brief_summary>
	<brief_title>A Study Establish Safety Tolerability Zimura® ( Anti-C5 Aptamer ) Combination With Anti-VEGF Therapy Subjects With Idiopathic Polypoidal Choroidal Vasculopathy ( IPCV )</brief_title>
	<detailed_description>Treatment experience ( Prior treatment anti-VEGF monotherapy ≥8 injection previous twelve ( 12 ) month ) subject IPCV receive 3 monthly ( Q4W ) injection Zimura® combination anti-VEGF therapy .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects either gender age ≥ 50 year Diagnosis IPCV Treatmentexperienced define prior treatment antiVEGF mono therapy ≥ 8 injection previous twelve ( 12 ) month Any intraocular surgery thermal laser within three ( 3 ) month trial entry Any prior thermal laser macular region , regardless indication Any ocular periocular infection twelve ( 12 ) week prior entry History follow condition procedure study eye : Rhegmatogenous retinal detachment , par plana vitrectomy , filter surgery ( e.g . trabeculectomy ) , glaucoma drainage device , corneal transplant Previous therapeutic radiation region study eye A diagnosis diabetic retinopathy ( presence microaneurysms vasculopathy and/or leakage retinal vasculature subject diabetes mellitus )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>idiopathic polypoidal choroidal vasculopathy</keyword>
	<keyword>IPCV</keyword>
	<keyword>Zimura®</keyword>
	<keyword>Avastin®</keyword>
	<keyword>Eylea®</keyword>
	<keyword>Lucentis®</keyword>
</DOC>